tirzepatide cv outcomes trial In patients with type 2 diabetes and atherosclerotic cardiovascular disease, was noninferior to dulaglutide with respect to major cardiovascular events. , , Read the full SURPASS-CVOT CARDIOVASCULAR EFFICACY OF TIRZEPATIDE IN
Pay in 4 interest-free payments of $6.91 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5




























